Bruker Corporation announced on April 24, 2025, the upcoming launch of its Beacon Discovery™ Optofluidic System at the American Association for Cancer Research (AACR) Annual Meeting 2025. This new benchtop system offers an accessible entry point into live single-cell functional analysis.
Building on Bruker’s proprietary Opto-Electrical Positioning (OEP) technology, Beacon Discovery complements the existing Beacon® platforms by prioritizing ease of use and flexibility with an intuitive user interface and customizable workflows. It allows researchers to conduct multi-parameter and temporal functional analysis over days or weeks.
With a substantially reduced cost of ownership and lower running costs, Beacon Discovery lowers the barrier to entry for researchers and core labs exploring immuno-oncology, infectious diseases, and autoimmune disorders. The platform is open for pre-orders, with commercial shipments expected later in 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.